NPPB and thalassemia: That study showed that even after the development of systolic dysfunction, there was not much difference in the BNP level in the thalassemia patients until the advanced clinical stages and suggested that the potential deficiency of BNP-related neurohormonal mechanisms might be responsible for impairing the clinical usefulness of this biomarker in β-thalassemia major patients.